This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Forum Summer 2018: Scientific Program
Share |

 

To view the final program, click here.


The future of biotechnology manufacturing has to enable the drivers facing the biotechnology industry – the need to decrease cost of goods, market globalization, allow for more rapid development of pipeline products, reduce risk to patient supply, increase product quality etc. The utilization of new technologies such as single use bioreactors, alternating tangential flow during fermentation, modular and closed process equipment, process analytical technology and Analytics of the Future will allow for a more robust process, reduced waste, increased titers, less non-conformances, less staffing required and dramatically less risk to technology transfer to new sites. The ability to utilize single use, pre-sterilized bioreactors and raw materials in a closed process eliminates the need for cleaning and steaming in place and reduces the risk of contaminations. The ability to create a modular, essentially identical, manufacturing sites across the globe means that technology transfer will require much less effort and risk. PAT and analytics of the future should allow for much more real time control of the process and less reliance on lot release assays, as well as driving more testing onto the manufacturing floor and reducing the costly footprint of the Quality Control Laboratories. In addition, advances in molecular modeling and cell cloning, as well as the ability to model processes such as column chromatography should allow for improved titers, less molecular variability and more rapid process development. However, the use of these novel technologies and the design of future biotechnology manufacturing sites will challenge regulatory paradigms; hence the need to partner with regulatory authorities as the future becomes a reality.



Monday, July 16, 2018

Morning
Continuous and Advances in Manufacturing - Upstream 
Session Chairs: Barry Cherney, Amgen Inc. and Sid Advant, Celgene Corporation 


Afternoon 
Continuous and Advances in Manufacturing - Downstream 
Session Chairs: Cristina Ausin, CDER, FDA and Steven Falcone, Sanofi 


Tuesday, July 17, 2018 

Morning 
Modelling and Control Strategies
Session Chairs: Sarah Kennett, Genentech, a Member of the Roche Group and Kim Wolfram, Biogen


Afternoon 
Emerging Analytical Technologies
Session Chairs: Michael Tarlov, NIST and Katia Ethiar, Health Canada





more Calendar

12/3/2018 » 12/4/2018
CMC Strategy Forum Japan 2018

Membership Software Powered by YourMembership  ::  Legal